Details of the Drug

General Information of Drug (ID: DMJFRCT)

Drug Name
Tasisulam
Synonyms Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C11H6BrCl2NO3S2
Canonical SMILES
C1=CC(=C(C=C1Cl)Cl)C(=O)NS(=O)(=O)C2=CC=C(S2)Br
InChI
InChI=1S/C11H6BrCl2NO3S2/c12-9-3-4-10(19-9)20(17,18)15-11(16)7-2-1-6(13)5-8(7)14/h1-5H,(H,15,16)
InChIKey
WWONFUQGBVOKOF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
10160238
CAS Number
519055-62-0
UNII
1YC4W9MSLJ
DrugBank ID
DB11941
TTD ID
D0X0KM
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

References

1 ClinicalTrials.gov (NCT01006252) A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma. U.S. National Institutes of Health.